Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Bone Miner Res. 2017 Jun 26;32(9):1945–1955. doi: 10.1002/jbmr.3183

Figure 3.

Figure 3

Subgroup analyses: Mean percent change from baseline, and treatment differences (immediate minus deferred ART groups) in spine (L1–L4) and total hip BMD are estimated within subgroups, with 95% confidence intervals. P-values are for tests of heterogeneity of the treatment difference across subgroups.

* Estimated in a longitudinal mixed model, adjusted for visit and baseline BMD. The interaction p-value for heterogeneity across subgroups was calculated using continuous variables for age, BMI, time since HIV diagnosis, CD4 count, and log10 HIV RNA levels.

** In the immediate ART group, a tenofovir-containing ART regimen was selected prior to randomization (“pre-specified”) for 162 participants. Of those who were pre-specified tenofovir and had the corresponding follow-up scans, 155 (96.3%).138 (97.2%), and 45 (97.8%) used tenofovir at years 1, 2, and 3, respectively.